Skip to main content

Table 4 Relationship between ARB use and hepatic steatosis after liver transplantation according to type of ARB, duration and cumulative dose of ARB

From: Angiotensin receptor blockers might be protective against hepatic steatosis after liver transplantation

 

With steatosis

Without steatosis

P-value

Mean duration (months)

23 ± 12.8

38.82 ± 20.11

0.024

Mean cDD (g)

37.77 ± 19. 43

67.98 ± 36.39

0.015

Type of ARB

  

0.722

Losartan

8 (30. 8%)

19 (69.2%)

 

Valsartan

3 (37.5%)

5 (62.5%)

 

Duration of use

  

0.037

< 20 months

5 (62.5%)

3 (23.1%)

 

≥ 20 months

6 (37.5%)

20 (76.9%)

 

Mean cDDD

  

0.048

< 20 (g)

4 (66.7%)

21 (75%)

 

≥ 20 (g)

7 (25%)

2 (33.3%)

 
  1. ARB: angiotensin receptor blockers, cDDD: cumulative defined daily dose; g: gram
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us